Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Biomarin Pharmaceutical (NASDAQ:BMRN) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 6 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 4 | 3 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $107.0, a high estimate of $120.00, and a low estimate of $86.00. This upward trend is evident, with the current average reflecting a 1.9% increase from the previous average price target of $105.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
The analysis...
Login or create a forever free account to read this news
Sign up/Log in